General
Preferred name
fenebrutinib
Synonyms
GDC-0853 ()
Fenebrutinib (GDC-0853) ()
G-02599853 ()
G02599853 ()
RG-7845 ()
RG7845 ()
RO-7010939 ()
RO7010939 ()
P&D ID
PD048241
CAS
1434048-34-6
Tags
available
drug candidate
Drug indication
Chronic idiopathic urticaria
Autoimmune disease
Solid tumour/cancer
Multiple sclerosis
Rheumatoid arthritis
Drug Status
investigational
Max Phase
3.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION RG7845 (GDC-0853) is a Bruton's tyrosine kinase (BTK) inhibitor, under investigation for therapeutic potential in difficult-to-treat autoimmune diseases. The compound is claimed in patent WO2013067274 .
DESCRIPTION RG7845 (GDC-0853) is a Bruton's tyrosine kinase (BTK) inhibitor, under investigation for therapeutic potential in difficult-to-treat autoimmune diseases. The compound is claimed in patent WO2013067274 . The proopsed INN is fenebrutinib.
DESCRIPTION Fenebrutinib (GDC-0853) is a potent, selective, orally available, and noncovalent bruton's tyrosine kinase (Btk) inhibitor with Kis of 0.91 nM, 1.6, 1.3, 12.6, and 3.4 nM for WT Btk, and the C481S, C481R, T474I, T474M mutants. Fenebrutinib has the potential for rheumatoid arthritis and systemic lupus erythematosus research[1].
PRICE 195
DESCRIPTION Fenebrutinib (RG7845, GDC-0853) is a reversible Bruton's tyrosine kinase (BTK) inhibitor, under investigation for therapeutic potential in difficult-to-treat autoimmune diseases, including multiple sclerosis . The compound is claimed in patent WO2013067274 . (GtoPdb)
DESCRIPTION Fenebrutinib (GDC-0853) is a selective and noncovalent inhibitor of Bruton's tyrosine kinase (Btk) with a Ki of 0.91 nM. (TargetMol Bioactive Compound Library)
Cell lines
1
Organisms
0
Compound Sets
12
Cayman Chemical Bioactives
21346
ChEMBL Drugs
CHEMBL4065122
Drug Repurposing Hub
DrugBank
DB14785
DrugMAP
DMBEL3Q
EUbOPEN Chemogenomics Library
EUB0001870
Guide to Pharmacology
9299
MedChem Express Bioactive Compound Library
HY-19834
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
fenebrutinib-gdc-0853
TargetMol Bioactive Compound Library
TQ0242
External IDs
22
Properties
(calculated by RDKit )
Molecular Weight
664.35
Hydrogen Bond Acceptors
11
Hydrogen Bond Donors
2
Rotatable Bonds
7
Ring Count
8
Aromatic Ring Count
4
cLogP
3.57
TPSA
120.99
Fraction CSP3
0.46
Chiral centers
1.0
Largest ring
6.0
QED
0.31
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
BTK
MOA
Bruton's Tyrosine Kinase (BTK) Inhibitor
Pathway
Angiogenesis
Tyrosine Kinase/Adaptors
Protein Tyrosine Kinase/RTK
Recommended Cell Concentration
100 nM
Source data